Insulin glargine

Viatris and Biocon Biologics Announce Launch of Interchangeable SEMGLEE® (insulin glargine-yfgn) Injection and Insulin Glargine (insulin glargine-yfgn) Injection

Retrieved on: 
Tuesday, November 16, 2021
TZD, Cancer, Upjohn, Security (finance), BSE, Insurance, Growth, COVID-19, Immunotherapy, Reg, Pfizer, Thiazolidinedione, Anaphylaxis, Regulation Fair Disclosure, Epidemic, Type 2 diabetes, Pandemic, Water retention, Blood, Diabetic ketoacidosis, Research, YouTube, ISIN, Cyprus Securities and Exchange Commission, Program, Patient, Adult, Private Securities Litigation Reform Act, NASDAQ, Hypoglycemia, NSE, Union, Insulin glargine, Multimedia, Rupee, Twitter, Prescription, SEC, Autoimmunity, Combination, European Free Trade Association, Adoption, Pharmacy, Caregiver, European Union, Diabetes, API, Infection, Insulin, Heart failure, LinkedIn, Hypokalemia, Medical error, Excipient, Pharmaceutical industry, Health insurance, Medical device, Fine chemical

Shreehas Tambe, dCEO, Biocon Biologics said: "At Biocon Biologics we are committed to expanding access to high-quality, affordable biologics to patients worldwide.

Key Points: 
  • Shreehas Tambe, dCEO, Biocon Biologics said: "At Biocon Biologics we are committed to expanding access to high-quality, affordable biologics to patients worldwide.
  • SEMGLEE (insulin glargine-yfgn) and Insulin Glargine (insulin glargine-yfgn), co-developed by Viatris andBiocon Biologics, are now available in the U.S. market.
  • The currently marketed non-interchangeable SEMGLEE (insulin glargine) is anticipated to be phased out by the end of the 2021 calendar year.
  • Viatris and Biocon Biologics have an exclusive collaboration for the development, manufacturing and commercialization of a broad portfolio of biosimilars and insulin analogs.

AMF Medical Welcomes Diabetes Industry Executives John Timberlake and Peter Gerhardsson to Its Board of Directors

Retrieved on: 
Tuesday, November 9, 2021
Corporation, Corporate social responsibility, VP, Business, NEOMA Business School, Retirement, Northwest Missouri State University, Health, Rouen Business School, CEO, Institute, MBA, Technology, Linköping University, Medtronic, Dexcom, Insulin glargine, Purdue University, Insulin, Board, International business development, Novo Nordisk, Toxicology, Medicine, Board of directors, Sigi, Lund University, Diabetes, International business, Patient, BS, Medical device, Pharmaceutical industry, Management

ECUBLENS, Switzerland, Nov. 9, 2021 /PRNewswire/ -- Diabetes industry experts John Timberlake and Peter Gerhardsson have joined AMF Medical's Board of Directors.

Key Points: 
  • ECUBLENS, Switzerland, Nov. 9, 2021 /PRNewswire/ -- Diabetes industry experts John Timberlake and Peter Gerhardsson have joined AMF Medical's Board of Directors.
  • John Timberlake is a diabetes industry veteran and is well known for his successful healthcare executive leadership.
  • Mr. Timberlake is currently the CEO and a board member of Berkshire Biomedical Corporation.
  • Mr. Timberlake said, "The team at AMF Medical designed Sigi with a clear focus on making insulin pump use very simple, effective, and more accessible.

Biosimilars 101: A Q&A with Sonia T. Oskouei, Cardinal Health Vice President of Biosimilars

Retrieved on: 
Thursday, November 4, 2021
Health equity, Biopharmaceutical, Safety, Adoption, View, Cancer, Elijah Cummings Lower Drug Costs Now Act, Pharmacy, Industry, Center, Adalimumab, Education, Eye, Knowledge, Food, Rheumatology, Manitoba Advanced Education and Literacy, Insulin glargine, Rheumatoid arthritis, Multimedia, Social media, Food and Drug Administration Safety and Innovation Act, Cardinal Health, Food and Drug Administration, AMD, Crohn's disease, Severe cognitive impairment, Insulin, Bacteria, Board, Biologics Price Competition and Innovation Act of 2009, Awareness, Kidney, Degenerative disease, CAH, Ophthalmology, NYSE, Innovation Act, Conditional sentence, Diabetes, Pharmacist, Patent, Interchangeability, Patient, Doctor of Pharmacy, FDA, Pharmaceutical industry, Generic drug

In recognition of the second annual Global Biosimilars Week a social media awareness campaign to help build understanding of and advocacy for biosimilars we spoke with Sonia T. Oskouei, PharmD and Cardinal Health's Vice President of Biosimilars.

Key Points: 
  • In recognition of the second annual Global Biosimilars Week a social media awareness campaign to help build understanding of and advocacy for biosimilars we spoke with Sonia T. Oskouei, PharmD and Cardinal Health's Vice President of Biosimilars.
  • Oskouei leads the company's overall biosimilar strategy and serves on the Board of Advisors for The Center for Biosimilars.
  • Q:Let's start with the basics: How do biosimilars compare to biologics, and why are they important to healthcare?
  • With 50 years in business, operations in more than 35 countries and approximately 44,000 employees globally, Cardinal Health is essential to care.

Adocia’s Partner Tonghua Dongbao Receives Clearance to Start Ultra-Rapid Insulin BioChaperone® Lispro Phase 3 Trial to Treat Type 1 and Type 2 Diabetes in China

Retrieved on: 
Thursday, October 14, 2021
Exenatide, World, Hyperglycemia, Diabetes, Peptide, Program, Euronext Paris, Eli Lilly, Industry, BC, Â, NMPA, Novo Nordisk, Combo, Trial of the century, Protein, National Medical Products Administration, Glycated hemoglobin, Absorption, Lists of diseases, Insulin glargine, ADOC, Patient, Syringe, CDE, Insulin, GLOBE, Center, IQVIA, Company, Hypoglycemia, Glucagon, CEO, Standard of care, Safety, Eli Lilly and Company, Partnership, Center for Drug Evaluation and Research, Obesity, Pharmaceutical industry, Medical device

BioChaperone Lispro (BC Lispro) is an ultra-rapid prandial insulin containing insulin lispro and Adocias proprietary technology BioChaperone.

Key Points: 
  • BioChaperone Lispro (BC Lispro) is an ultra-rapid prandial insulin containing insulin lispro and Adocias proprietary technology BioChaperone.
  • For more information on BC Lispro, visit our website: https://www.adocia.com/products/biochaperone-ultra-fast-analog-insulin/
    Adocias partner Tonghua Dongbao is one of the leading insulin providers in Asia.
  • In 2018, Adocia and partner Tonghua Dongbao signed a strategic alliance to develop and commercialize BC Lispro in China and other Asian territories.
  • Tonghua Dongbao also supplies insulin lispro and insulin glargine to Adocia for the worldwide market, except China.

Adocia’s partner Tonghua Dongbao Receives Clearance to Start Ultra-Rapid Insulin BioChaperone® Lispro Phase 3 Trial to Treat Type 1 and Type 2 Diabetes in China

Retrieved on: 
Thursday, October 14, 2021
Exenatide, World, Hyperglycemia, Diabetes, Peptide, Program, Euronext Paris, Eli Lilly, Industry, BC, NMPA, Novo Nordisk, Combo, Trial of the century, Protein, National Medical Products Administration, Glycated hemoglobin, Absorption, Lists of diseases, Insulin glargine, ADOC, Patient, Syringe, CDE, Insulin, GLOBE, Center, IQVIA, Company, Hypoglycemia, Glucagon, CEO, Standard of care, Safety, Eli Lilly and Company, Partnership, Center for Drug Evaluation and Research, Obesity, Pharmaceutical industry, Medical device

BioChaperone Lispro (BC Lispro) is an ultra-rapid prandial insulin containing insulin lispro and Adocias proprietary technology BioChaperone.

Key Points: 
  • BioChaperone Lispro (BC Lispro) is an ultra-rapid prandial insulin containing insulin lispro and Adocias proprietary technology BioChaperone.
  • For more information on BC Lispro, visit our website: https://www.adocia.com/products/biochaperone-ultra-fast-analog-insulin/
    Adocias partner Tonghua Dongbao is one of leading insulin providers in Asia.
  • In 2018, Adocia and partner Tonghua Dongbao signed a strategic alliance to develop and commercialize BC Lispro in China and other Asian territories.
  • Tonghua Dongbao also supplies insulin lispro and insulin glargine to Adocia for the worldwide market, except China.

Adocia to Participate in the H.C. Wainwright 23rd Annual Global Investment Conference

Retrieved on: 
Friday, September 10, 2021

The H.C. Wainwright webcast will be available on-demand to those attending the conference virtually starting Monday, September 13th, 2021 at 7:00 AM ET.

Key Points: 
  • The H.C. Wainwright webcast will be available on-demand to those attending the conference virtually starting Monday, September 13th, 2021 at 7:00 AM ET.
  • Investors attending the conference virtually who are interested in meeting with Company management should contact their H.C. Wainwright representative.
  • Adocia is a clinical-stage biotechnology company that specializes in the development of innovative formulations of therapeutic proteins and peptides for the treatment of diabetes and metabolic diseases.
  • The clinical pipeline also includes an aqueous formulation of human glucagon (BioChaperone Glucagon) for the treatment of hypoglycemia.

Oral Biologics & Biosimilar Drugs Global Market Report 2021: COVID-19 Impacts, Growth and Changes to 2030 - ResearchAndMarkets.com

Retrieved on: 
Friday, August 6, 2021
Biotechnology, Pharmaceutical, Health, Growth, Peptide, Arthritis, Alzheimer's disease, AstraZeneca, EMA, Food, Prevalence, Enterocolitis, Novartis, Vaccine, Sarcoma, Crohn's disease, COVID-19, Insulin, Therapy, Technology, Disease, Pharmacy, Partnership, Psoriasis, Multiple myeloma, Cancer, Diabetes, Biosimilar, Mylan, Conditional sentence, Eli Lilly and Company, Carcinoma, Biocon, European Medicines Agency, Asthma, Asia, Allergan, HIV/AIDS, Protein, Novo Nordisk, Multiple sclerosis, Government, US Foods, Insulin glargine, Pharmaceutical industry, Generic drug

The "Oral Biologics & Biosimilar Drugs Global Market Report 2021: COVID-19 Growth and Change to 2030" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Oral Biologics & Biosimilar Drugs Global Market Report 2021: COVID-19 Growth and Change to 2030" report has been added to ResearchAndMarkets.com's offering.
  • The oral biologics and biosimilar market consist of sales of oral biologics and biosimilar products and related services used to treat chronic diseases such as diabetes, arthritis, cancer.
  • The oral biologics and biosimilar market comprise of biologics and biosimilar drugs taken orally for the targeted treatment of Alzheimer's, multiple sclerosis, HIV/AIDS and other serious conditions.
  • North America was the largest region in the global oral biologics & biosimilar drugs market, accounting for 46% of the market in 2019.

Viatris Inc. and Biocon Biologics Receive Historic Approval for First Interchangeable Biosimilar Semglee® (insulin glargine-yfgn injection) for the Treatment of Diabetes

Retrieved on: 
Thursday, July 29, 2021
Life sciences, Biology, Branches of biology, Biotechnology, Peptide hormones, Recombinant proteins, Biocon, Biosimilar, Insulin glargine, Kiran Mazumdar-Shaw, Insulin, Biopharmaceutical

The company is eligible to have exclusivity for 12 months before the FDA can approve another biosimilar interchangeable to Lantus.

Key Points: 
  • The company is eligible to have exclusivity for 12 months before the FDA can approve another biosimilar interchangeable to Lantus.
  • Semglee is indicated to control high blood sugar in adults with Type 2 diabetes and adults and pediatric patients with Type 1 diabetes.
  • Biocon Biologics, Executive Chairperson, Kiran Mazumdar-Shaw said: "We are extremely proud to be the first to obtain approval of an interchangeable Biosimilar product in the U.S.
  • This will allow pharmacy level substitution and thereby provide convenient and affordable access to Semglee, a quality Biosimilar Insulin Glargine."

FDA Approves First Interchangeable Biosimilar Insulin Product for Treatment of Diabetes

Retrieved on: 
Wednesday, July 28, 2021
Branches of biology, Peptide hormones, Recombinant proteins, Clinical medicine, Hormones, Biosimilar, Insulin glargine, Insulin analog, Insulin

Semglee (insulin glargine-yfgn) is both biosimilar to, and interchangeable with (can be substituted for), its reference product Lantus (insulin glargine), a long-acting insulin analog.

Key Points: 
  • Semglee (insulin glargine-yfgn) is both biosimilar to, and interchangeable with (can be substituted for), its reference product Lantus (insulin glargine), a long-acting insulin analog.
  • Semglee (insulin glargine-yfgn) is the first interchangeable biosimilar product approved in the U.S. for the treatment of diabetes.
  • "This is a momentous day for people who rely daily on insulin for treatment of diabetes, as biosimilar and interchangeable biosimilar products have the potential to greatly reduce health care costs," said Acting FDA Commissioner Janet Woodcock, M.D.
  • The FDA released new materials for health care providers to enhance understanding about biosimilar and interchangeable biosimilar products, including a fact sheet about interchangeable biosimilar products.

United States Insulin Injection Pen Market Report 2021: $5.5 Billion Growth, Trends and Forecasts to 2027 - ResearchAndMarkets.com

Retrieved on: 
Tuesday, April 13, 2021
Health, Diabetes, Branches of biology, Clinical medicine, Drugs, Peptide hormones, Recombinant proteins, Insulin, Regular insulin, Insulin glargine, Insulin pump

b'The United States market for the insulin injection pen market is expected to touch US$ 5.5 billion by the year-end of 2027.\nA Comprehensive List of Key Market Players Along with the Analysis of their Current Insulin Injection Pen Portfolios, Business Overview, and Current Development\n'

Key Points: 

b'The United States market for the insulin injection pen market is expected to touch US$ 5.5 billion by the year-end of 2027.\nA Comprehensive List of Key Market Players Along with the Analysis of their Current Insulin Injection Pen Portfolios, Business Overview, and Current Development\n'